2011, FDA, Fraud and Licensing - Health Care Compliance Brief

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2011

FDA

Fraud

Licensing

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

DECEMBER 29, 2023

2023) ( Buckman preemption barred MDL asserting fraud on EPA), cert. Since the FDA requires pre-approval of any warnings about off-label uses, preemption at some point should have been pre-ordained under the Mensing ( 2011+1 ) independence principle, but off-label use did not really figure in Zofran ’s analysis. Monsanto Co. ,

FDA

FDA US Department of Health and Human Services COVID-19 Informed Consent

TwIqbal And Punitive Damages

Drug & Device Law

MARCH 7, 2022

Here, Plaintiffs fail to supply factual support showing Defendant acted with “oppression, fraud, or malice,” relying instead upon conclusory allegations. 2011 WL 2149095, at *5 (N.D. May 31, 2011). “[I]n These allegations lack any contention or inference that [defendant] withheld or misrepresented information to the FDA. . .,

Fraud

Fraud FDA Licensing Pharmaceutical Industry

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

TwIqbal And Punitive Damages

Stay Connected